Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis

References

• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347–365.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). COPD predicted to be third leading cause of death in 2030. World Health Organization 2012. Available from: http://www.who.int/respiratory/copd/WorldHealthStatistics˙2008/en/index.html# ( accessed 25 December 2012).
   Google Scholar
• Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370(9589):765–773.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD updated 2014: Global Initiative for Chronic Obstructive Lung disease, Inc. Available from: http://www.goldcopd.org; 2014 ( accessed 18 May 2014).
   Google Scholar
• Barnes PJ. The role of anticholinergics in chronic obstructive pulmonary disease. Am J Med 2004; 117 Suppl 12A:24S–32S.
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee, W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23(6):932–946.
   PubMed Web of Science ®Google Scholar
• Hodder R. Tiotropium is superior to salmeterol in reducing frequency of exacerbations: but the effect of adding tiotropium to the combination of inhaled corticosteroid and long-acting beta(2)-agonist remains unclear. Evid Based Med 2012; 17(3):93–95.
   PubMedGoogle Scholar
• Moulton BC, Fryer AD. Muscarinic receptor antagonists, from folklore to pharmacology; finding drugs that actually work in asthma and COPD. Br J Pharmacol 2011; 163(1):44–52.
   PubMed Web of Science ®Google Scholar
• Jacoby DB, Fryer AD. Anticholinergic therapy for airway diseases. Life Sci 2001; 68(22–23):2565–2572.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. Drug Healthc Patient Saf 2013; 5:49–55.
   PubMedGoogle Scholar
• Reid DJ, Pham NT. Emerging therapeutic options for the management of COPD. Clin Med Insights Circ Respir Pulm Med 2013; 7:7–15.
   PubMedGoogle Scholar
• U.S. Federal Drug Administration (FDA). Drug approval package; Tudorza Pressair (aclidinium bromide) inhalation powder. United States Food, Drug Administration 2012. Available from: http://www.accessdata.fda.gov/drugsatfdadocs/nda/2012/202450Orig1s000TOC.cfm ( accessed 25 December 2012).
   Google Scholar
• Gavalda A, Miralpeix M, Ramos I, et al. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profie. J Pharmacol Exp Ther 2009; 331(2):740–751.
   PubMed Web of Science ®Google Scholar
• Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009; 330(2):660–668.
   PubMed Web of Science ®Google Scholar
• Sentellas S, Ramos I, Alberti J, et al. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010; 39(5):283–290.
   PubMed Web of Science ®Google Scholar
• Alberti J, Martinet A, Sentellas S, Salva M. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos 2010; 38(7):1202–1210.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155(3):179–191 .
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145(6):1321–1327.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85(6):751–758.
   PubMed Web of Science ®Google Scholar
• Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res 2011; 12:55.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012; 9(2):90–101.
   PubMedGoogle Scholar
• Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig 2013; 33(12):893–904.
   PubMed Web of Science ®Google Scholar
• Singh D JP, Bateman E, Korn S, et al. Evaluation of the efficacy and safety of two doses of aclidinium and formoterol in fixed-dose combination in patients with COPD: the ACLIFORM study. Chest 2014; 145:375A.
   Google Scholar
• Jones PW SD, Bateman ED, Agusti A, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40(4):830–836.
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Rennard S, Mergel V, Garcia Gil E, Leselbaum A, Caracta C. The AUGMENT COPD trial: efficacy and safety of a fixed-dose combination of aclidinium bromide and formoterol fumarate in COPD patients. Chest 2014; 145:426A .
   Web of Science ®Google Scholar
• Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther 2013; 30(4):354–368.
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Jones P, Ferguson GT, Rekeda L, Garcia Gil E, Caracta C. Aclidinium bromide improves lung function in a wide range of patients with moderate to severe COPD: Pooled subgroup analysis of the ACCORD COPD I and II and ATTAIN trials. Chest 2013; 144(4˙Meeting abstracts):746A .
   Google Scholar
• Suppli Ulrik C. Aclidinium bromide: Clinical benefit in patients with moderate to severe COPD. Open Respir Med J 2012, 6:150–154.
   PubMedGoogle Scholar
• Donohue J, Tashkin D, Ferguson GT, Kowey P, Rekeda L, Shrestha P. Long-term cardiovascular safety of aclidinium bromide in patients with COPD. Chest 2013; 144(4˙Meeting abstracts):716A .
   Google Scholar
• Ferguson GT, Kerwin E, Singh D, Kowey P, Rekeda L, Shrestha P. Cardiovascular safety of aclidinium bromide in COPD: pooled results from three placebo-controlled studies. Chest 2013; 144(4˙Meeting abstracts):715A .
   Google Scholar
• Almirall, S. A. Efficacy, safety and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo for 28-weeks treatment in patients with moderate to severe stable chronic obstructive pulmonary disease (COPD). Available from: http://clinicaltrials.gov/ct2/show/NCT01572792 ( accessed 1 May 2014) .
   Google Scholar
• Evaluate the effect of aclidinium bromide on long-term cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD (ASCENT COPD). Available from: http://clinicaltrials.gov/ct2/show/NCT01966107 ( accessed 1 May 2014) .
   Google Scholar